Investor Relations
Agreement to manufacture 50 g siRNA
Codexis signs agreement to support preclinical work using the ECO Synthesis Manufacturing Platform for cardiovascular indication
Codexis signs agreement to support preclinical work using the ECO Synthesis Manufacturing Platform for cardiovascular indication
Mar 11, 2026 4:30 pm EST
View our latest Investor Presentation to find the most recent investor-related information.
Sign up today and receive company updates straight to your inbox.
Codexis is a leading enzyme engineering company powering scalable, sustainable solutions for therapeutic development. We unlock therapeutic possibilities previously out of reach — from next-gen RNA medicines to precision diagnostic enzymes. With our proprietary CodeEvolver® platform and ECO Synthesis™ platform, we create manufacturing solutions for challenges once thought unsolvable, delivering enzymes that outperform legacy methods across RNAi therapeutics, diagnostics, and small molecule manufacturing. Our enzyme-powered processes drive measurable impact with fewer impurities, faster timelines, and reduced waste and energy use across applications.
Codexis, Inc.
200 Penobscot Drive
Redwood City, California 94063
T: 650-421-8100
media@codexis.com
Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
United States
M: 650-421-8399
ir@codexis.com
EQ Shareowner Services
1110 Centre Pointe Curve
Suite 101
Mendota Heights, MN 55120-4100
T: 800-468-9716
https://www.shareowneronline.com